MaaT Pharma SA (MAAT.PA)
EUR 8.1
(1.0%)
EUR 8.1
(1.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 42.93 Million EUR | -4.01% |
| 2022 | 44.72 Million EUR | -9.5% |
| 2021 | 49.42 Million EUR | 103.58% |
| 2020 | 24.27 Million EUR | 197.14% |
| 2019 | 8.17 Million EUR | 38.83% |
| 2018 | 5.88 Million EUR | -36.46% |
| 2017 | 9.26 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 50.92 Million EUR | 0.0% |
| 2024 Q1 | 50.92 Million EUR | 18.62% |
| 2023 FY | 42.93 Million EUR | -4.01% |
| 2023 Q1 | 49.78 Million EUR | 11.3% |
| 2023 Q4 | 42.93 Million EUR | 0.0% |
| 2023 Q3 | 42.93 Million EUR | -13.76% |
| 2023 Q2 | 49.78 Million EUR | 0.0% |
| 2022 Q4 | 44.72 Million EUR | 0.0% |
| 2022 Q3 | 44.72 Million EUR | -3.93% |
| 2022 Q2 | 46.55 Million EUR | 0.0% |
| 2022 Q1 | 46.55 Million EUR | -5.8% |
| 2022 FY | 44.72 Million EUR | -9.5% |
| 2021 Q1 | 21.95 Million EUR | -9.58% |
| 2021 FY | 49.42 Million EUR | 103.58% |
| 2021 Q4 | 49.42 Million EUR | 0.0% |
| 2021 Q3 | 49.42 Million EUR | 125.15% |
| 2021 Q2 | 21.95 Million EUR | 0.0% |
| 2020 Q4 | 24.27 Million EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q3 | 24.27 Million EUR | 0.0% |
| 2020 FY | 24.27 Million EUR | 197.14% |
| 2019 FY | 8.17 Million EUR | 38.83% |
| 2018 FY | 5.88 Million EUR | -36.46% |
| 2017 FY | 9.26 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -191.849% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 86.874% |
| Adocia SA | 24.95 Million EUR | -72.027% |
| Aelis Farma SA | 26.28 Million EUR | -63.354% |
| Biophytis S.A. | 11.93 Million EUR | -259.677% |
| Advicenne S.A. | 12.4 Million EUR | -246.022% |
| genOway Société anonyme | 31.84 Million EUR | -34.824% |
| IntegraGen SA | 8 Million EUR | -436.614% |
| Medesis Pharma S.A. | 1.92 Million EUR | -2128.636% |
| Neovacs S.A. | 47.53 Million EUR | 9.683% |
| NFL Biosciences SA | 3.97 Million EUR | -981.214% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -187.878% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -1045.813% |
| Sensorion SA | 46.49 Million EUR | 7.664% |
| Theranexus Société Anonyme | 7.23 Million EUR | -493.155% |
| TME Pharma N.V. | 2.49 Million EUR | -1623.444% |
| Valbiotis SA | 33.24 Million EUR | -29.124% |
| TheraVet SA | 7.53 Million EUR | -469.816% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -21.707% |
| argenx SE | 4.11 Billion EUR | 98.956% |
| BioSenic S.A. | 9.55 Million EUR | -349.116% |
| Celyad Oncology SA | 16.28 Million EUR | -163.672% |
| DBV Technologies S.A. | 165.65 Million USD | 74.083% |
| Galapagos NV | 4.35 Billion EUR | 99.015% |
| Genfit S.A. | 173.87 Million EUR | 75.309% |
| GeNeuro SA | 6.31 Million EUR | -580.052% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 9.962% |
| Innate Pharma S.A. | 184.19 Million EUR | 76.692% |
| Inventiva S.A. | 69.13 Million EUR | 37.906% |
| MedinCell S.A. | 36.94 Million EUR | -16.193% |
| Nanobiotix S.A. | 93.89 Million EUR | 54.279% |
| Onward Medical N.V. | 43.62 Million EUR | 1.6% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 59.84% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 47.581% |
| Oxurion NV | 6.55 Million EUR | -555.435% |
| Pharming Group N.V. | 426.33 Million EUR | 89.93% |
| Poxel S.A. | 4.82 Million EUR | -790.131% |
| GenSight Biologics S.A. | 9.08 Million EUR | -372.444% |
| Transgene SA | 45.21 Million EUR | 5.056% |
| Financière de Tubize SA | 1.92 Billion EUR | 97.764% |
| UCB SA | 15.53 Billion EUR | 99.724% |
| Valneva SE | 469.39 Million EUR | 90.854% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -39.255% |